RegulatoryApr 17, 2026, 09:17 AM
US Admin to Evaluate Ibogaine; Psyence BioMed Poised for Research
AI Summary
Psyence Biomedical Ltd. acknowledged reports of a potential U.S. executive order to evaluate ibogaine's safety and therapeutic potential, a compound they are studying for PTSD and addiction. The company welcomes this move, emphasizing the need for rigorous, regulated research. Psyence BioMed is well-positioned with its GMP-compliant manufacturing through PsyLabs and an ethically sourced ibogaine supply chain, ready to support the evolving regulatory environment and clinical research.
Key Highlights
- US administration preparing executive order to evaluate ibogaine.
- Psyence BioMed welcomes efforts to advance structured, evidence-based research.
- Company holds a leading position in GMP-compliant ibogaine manufacturing via PsyLabs.
- Developed a responsible and ethically sourced ibogaine supply chain in Africa.
- Ibogaine remains a Schedule I substance in the United States.
Price Impact
More from PBM